Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis by Coates, LC et al.
Original article
Performance of composite measures used in a trial
of etanercept and methotrexate as monotherapy or
in combination in psoriatic arthritis
Laura C. Coates 1, Joseph F. Merola2, Philip J. Mease 3, Alexis Ogdie4,
Dafna D. Gladman5, Vibeke Strand6, Leonieke J. J. van Mens7, Lyrica Liu8,
Priscilla K. Yen9, David H. Collier10, Gregory Kricorian10, James B. Chung10
and Philip S. Helliwell11
Abstract
Objectives. To examine which composite measures are most sensitive to change when measuring psoriatic arth-
ritis (PsA) disease activity, analyses compared the responsiveness of composite measures used in a 48-week
randomized, controlled trial of MTX and etanercept in patients with PsA.
Methods. The trial randomised 851 patients to receive weekly: MTX (20 mg/week), etanercept (50 mg/week) or MTX
plus etanercept. Dichotomous composite measures examined included ACR 20/50/70 responses, minimal disease
activity (MDA) and very low disease activity (VLDA). Continuous composite measures examined included Disease
Activity Score (28 joints) using CRP (DAS28-CRP), Clinical Disease Activity Index (CDAI), Simplified Disease Activity
Index (SDAI), Disease Activity for Psoriatic Arthritis (DAPSA) and Psoriatic Arthritis Disease Activity Score (PASDAS).
Results. At week 24, etanercept-treated groups were significantly more effective than MTX monotherapy to achieve
ACR 20 (primary end point) and MDA (key secondary end point). When examining score changes from baseline at
week 24 across the five continuous composite measures, PASDAS demonstrated relatively greater changes in the
etanercept-treated groups compared with MTX monotherapy and had the largest effect size and standardized re-
sponse. Joint count changes drove overall score changes at week 24 from baseline in all the continuous composite
measures except for PASDAS, which was driven by the Physician and Patient Global Assessments.
Conclusion. PASDAS was the most sensitive continuous composite measure examined with results that mirrored
the protocol-defined primary and key secondary outcomes. Composite measures with multiple domains, such as
PASDAS, may better quantify change in PsA disease burden.
Trail registration. https://ClinicalTrials.gov, number NCT02376790.
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Introduction
Psoriatic arthritis (PsA) is a systemic, immune-mediated
disease with multiple manifestations including arthritis,
psoriasis, enthesitis and dactylitis [1]. Because compos-
ite measures provide a summary outcome across mul-
tiple disease manifestations at a specific time point [2],
they may be particularly useful for evaluating disease
activity and advising treatment decisions in conditions
such as PsA that have multi-organ system manifesta-
tions [3]. Composite measures initially used for PsA
included the ACR response criteria [4] and Disease
Activity Score (28 joints) (DAS28) [5, 6], which were
developed for use in rheumatoid arthritis, with an em-
phasis on peripheral arthritis [7]. Composite measures
later developed for PsA included the Disease Activity
[Index] in PsA (DAPSA) [8], which evaluates a 66/68-joint
count that is recommended for PsA; the PsA Disease
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Activity Score (PASDAS) [9], which includes the 66/68-
joint count as well as non-articular domains such as
enthesitis and dactylitis; and the Composite Psoriatic
Disease Activity Index (CPDAI) [10], which includes non-
articular domains such as enthesitis, dactylitis and skin
disease [9–11]. DAS28, DAPSA, CPDAI and PASDAS
are all continuous measures where remission is defined
as a level below a set cutoff value. Minimal disease ac-
tivity (MDA) is another composite measure developed
for use in PsA that accounts for more than joint involve-
ment alone but is a dichotomous measure representing
a state of disease activity [12, 13].
Several prior interventional trials have reported
PASDAS to be the most sensitive to change of those
composite measures examined [3, 14]. However, it has
yet to be definitively determined which composite meas-
ures have the greatest sensitivity for measuring change
in PsA disease activity and the strongest relationship to
patient outcomes. The Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) and Outcome Measures in Rheumatology
(OMERACT) were unable to reach a consensus in 2018
as to which composite measures to recommend for use
in PsA and instead recommended that these measures
be further compared and validated [7].
The objective of the study described here was to
compare the responsiveness and psychometric proper-
ties (e.g. effect size and standardized response) of com-
posite measures commonly used in PsA. To address
this objective, the performance characteristics of the
composite measures used in The Study of Etanercept
And Methotrexate in Combination or as Monotherapy in
Subjects with Psoriatic Arthritis (SEAM-PsA) were exam-
ined. This phase 3, double-blind, 48-week, randomized,
controlled trial (RCT) was the first study to directly com-
pare MTX with etanercept in patients with PsA by inves-
tigating the efficacy of MTX monotherapy compared
with both etanercept monotherapy and MTX combined
with etanercept [15, 16]. SEAM-PsA is an ideal dataset
for examining PsA composite measures as it is a robust
trial with over 280 patients in each of the three treatment
groups and collected data based on five continuous
composite measures [DAS28, Clinical Disease Activity
Index (CDAI), Simplified Disease Activity Index (SDAI),
DAPSA and PASDAS].
To more thoroughly examine the composite measure
data collected during the SEAM-PsA trial, the explora-
tory analyses described here investigated the relative
performance of all five continuous composite measures
used in SEAM-PsA and analysed which individual com-
ponents within each composite measure contributed the
most input to the change in composite measure out-
comes. Because previous studies comparing PsA com-
posite measures used data from placebo-controlled
trials [3, 14], this is the first analysis comparing the per-
formance of composite measures in a PsA trial with an
active-comparator design.
Methods
Study design and patient population
The SEAM-PsA study design has been published [15,
16]. In brief, this 48-week, double-blind, international
RCT enrolled patients 18 years old with active PsA
[based on Classification Criteria for Psoriatic Arthritis
(CASPAR)] [17], naı¨ve to etanercept and other biologic
agents and with no prior use of MTX for PsA (prior treat-
ment with MTX was allowed for psoriasis). At screening
and baseline, patients had to have  three tender and 
three swollen joints (66/68-joint count) and an active
psoriatic skin lesion 2 cm in diameter. Patients were
randomized 1:1:1 to receive weekly treatment with: (i)
oral MTX (target of 20 mg/week) plus subcutaneous pla-
cebo, (ii) subcutaneous etanercept (50 mg/week) plus
oral placebo, or (iii) subcutaneous etanercept (50 mg/
week) plus oral MTX (target of 20 mg/week). MTX, sup-
plied as 2.5-mg tablets in capsules, was initiated at
10 mg/week and titrated up to 20 mg/week over a 4-
week period. The MTX dose could be reduced to as low
as 10 mg/week in response to MTX-related intolerability
or toxicities.
On or after week 24, patients with inadequate
responses (defined as <20% improvements from base-
line in tender and swollen joint counts) received rescue
therapy with etanercept plus MTX until week 48.
Because rescue therapy was administered on or after
week 24, efficacy analyses described here focused on
week-24 outcomes.
The SEAM-PsA RCT was conducted in accordance
with the Helsinki Declaration with all patients providing
Rheumatology key messages
. The PASDAS composite measure performed more effectively in this trial compared with joint-focused composite
measures.
. DAS28-CRP, CDAI, SDAI and DAPSA changes are driven by joint counts; PASDAS changes by global
assessments.
. PASDAS may be the most effective continuous composite measure for evaluating psoriatic arthritis disease
activity.
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written, informed consent and each participating site
obtaining protocol approval by an institutional review
board.
Study endpoints
The five dichotomous composite measures employed
were: ACR 20 [4], ACR 50 [18], ACR 70 [18], MDA [13]
and very low disease activity (VLDA) [19]. The five con-
tinuous composite measures employed were: DAS28-
CRP [5, 6], CDAI [20], SDAI [21], DAPSA [8] and
PASDAS [9]. Supplementary Table S1, available at
Rheumatology online lists the components of each
composite measure and how results for each measure
are calculated. The primary end point was the percent-
age of patients achieving a 20% improvement in ACR
criteria (ACR 20 response) at week 24; the key second-
ary end point was the percentage of patients achieving
MDA at week 24. Secondary endpoints included the
percentages of patients achieving ACR 50, ACR 70 and
VLDA at week 24 as well as changes from baseline at
week 24 in DAS28-CRP, CDAI, SDAI, DAPSA and
PASDAS. A publication of the primary results of this
trial reported that at week 24, etanercept monotherapy
and etanercept plus MTX were statistically significantly
more effective than MTX monotherapy in the percent-
age of patients achieving an ACR 20 response (primary
end point) and MDA (key secondary end point) [15].
Mean improvements from baseline at week 24 in
PASDAS scores were greater in the etanercept-treated
groups compared with MTX monotherapy, while only
modest differences were evident between the three
treatment groups for the DAPSA score mean change
from baseline [15]. Safety results at week 48 indicated
no new safety signals associated with use of etaner-
cept or MTX; rates of nausea were higher in the two
MTX-treated groups compared with etanercept mono-
therapy [15].
Statistical analyses
SEAM-PsA was powered to examine the ACR 20 pri-
mary end point and the MDA key secondary end point
at week 24. All other efficacy endpoints were analysed
as observed and without adjustment for multiplicity;
therefore, P-values for these other efficacy endpoints
are considered descriptive. The Cochran-Mantel-
Haenszel test was used for all between-treatment com-
parisons and was adjusted using stratification factors of
baseline body mass index status of 30 kg/m2 or
>30 kg/m2 and prior use of a non-biologic disease-mod-
ifying antirheumatic drug.
To compare the performance of the continuous com-
posite measures (DAS28-CRP, CDAI, SDAI, DAPSA and
PASDAS), exploratory analyses examined the effect
sizes and standardized responses at week 24 in each
treatment group. To calculate the effect size of each
continuous composite measure, the following formula
was used: (baseline mean  post baseline mean)/S.D. of
baseline mean [22]. To calculate the standardized
response of each composite measure, the following for-
mula was used: (baseline mean  post baseline mean)/
S.D. of change from baseline for that visit in the same
treatment group [22].
Exploratory analyses also examined the contribution
of the change of individual components within each con-
tinuous composite measure to the overall changes in
each composite score from baseline to week 24 using
the following formula: [change from baseline in each
component score/change from baseline in overall score].
For the PASDAS composite measure, analyses of driv-
ers of composite results were performed on the full ana-
lysis set (all randomized patients), in a patient subgroup
with Leeds Enthesitis Index of >0 at baseline, and in an-
other patient subgroup with Tender Dactylitis Count >0
at baseline. Analyses were performed using SAS version
9.4 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
In SEAM-PsA, 284 patients were randomised to MTX
monotherapy, 284 to etanercept monotherapy and 283 to
MTX plus etanercept (combination therapy); 691 patients
(81.2% of those enrolled) completed the trial [15].
Baseline disease characteristics and disease activity were
generally well balanced across the three treatment groups
(Table 1). In this trial, 90.7% of patients were white and
the mean (S.D.) age was 48.4 (13.1) years. Most patients
were early in the course of their disease as the mean
(S.D.) duration of PsA was 3.2 (6.3) years (median
0.6 years), with 56% of patients having disease duration
of 2 years. Forty-two patients had received prior MTX
for psoriasis. During study weeks 4–24, the mean MTX
dose maintained by patients in the MTX-treated groups
was >18.8 mg (median 20 mg).
Efficacy outcomes from the dichotomous and
continuous composite measures
Table 2 summarizes the percentages of patients who
achieved dichotomous composite measure outcomes
(ACR 20/50/70, MDA and VLDA) at week 24 [15] and the
mean changes from baseline at week 24 in the continu-
ous composite measures (DAS28-CRP, CDAI, SDAI,
DAPSA and PASDAS). As previously reported, more
patients achieved ACR/MDA/VLDA responses at week
24 in the etanercept-treated groups compared with MTX
monotherapy [15] (Table 2). Similarly, greater mean
changes from baseline at week 24 were evident in the
etanercept-treated groups compared with MTX mono-
therapy in the DAS28-CRP and PASDAS continuous
composite measures (Table 2). Among the continuous
composite measures, differences between the
etanercept-treated groups and MTX monotherapy were
most pronounced in PASDAS (P <0.001 for MTX mono-
therapy vs etanercept monotherapy and P <0.001 for
MTX monotherapy vs combination therapy) and were
Performance of composite measures
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consistent with the efficacy results obtained using the
dichotomous composite measures (Table 2). Mean
changes from baseline at week 24 in the articular-
focused measures of CDAI, SDAI and DAPSA were simi-
lar across all three treatment groups though numerically
higher in the etanercept-treated groups compared with
MTX monotherapy (Table 2). The efficacy outcomes of
the composite measures at weeks 12 and 48 (data not
shown) produced comparable trends to those seen at
week 24, indicating that the composite measures had
stable performance characteristics over time in this trial.
The only difference was a greater improvement that
occurred in the etanercept-containing arms during the
first 3 months, which resulted in a larger difference be-
tween the MTX monotherapy and etanercept-containing
arms at week 12.
Relative performance of the continuous composite
measures
To examine the relative performance of the continuous
composite measures, effect sizes and standardized
responses were calculated for each measure. Results
indicated that the etanercept-treated groups had numer-
ically larger effect sizes and standardized responses
than MTX monotherapy across all five continuous com-
posite measures (Fig. 1A and B).
The most pronounced difference between the
etanercept-treated groups and MTX monotherapy was
with the PASDAS composite measure. For the effect
sizes (Fig. 1A), the difference between etanercept mono-
therapy and MTX monotherapy ranged from 0.15–0.36
across the four joint-focused measures and was 0.7
TABLE 1 Baseline characteristics and disease activity
MTX
monotherapy
(n5284)
Etanercept
monotherapy
(n5 284)
Combination
therapy
(n5 283)
Age in years, mean (S.D.) 48.7 (13.1) 48.5 (13.5) 48.1 (12.7)
Female sex, n (%) 160 (56.3) 133 (46.8) 139 (49.1)
White race, n (%) 255 (89.8) 252 (88.7) 265 (93.6)
Duration of PsA in years, mean (S.D.) [n]a 3.6 (6.8) [231] 3.1 (6.0) [222] 3.0 (6.0) [231]
Median (Q1, Q3) [n] 0.9 (0.1, 3.3) [231] 0.6 (0.1, 3.0) [222] 0.5 (0.1, 3.0) [231]
Prior use of nonbiologic DMARD, n (%) 38 (13.4) 26 (9.2) 43 (15.2)
Body mass index (kg/m2), mean (S.D.) [n] 30.6 (7.1) [284] 30.4 (6.6) [283] 30.0 (6.7) [283]
30 kg/m2, n (%) 146 (51.4) 153 (53.9) 160 (56.5)
>30 kg/m2, n (%) 138 (48.6) 130 (45.8) 123 (43.5)
CRP, mean (S.D.) mg/L [n] 10.5 (16.3) [284] 10.7 (15.6) [282] 8.7 (11.6) [283]
mTSS, mean (S.E.) [n] 2.76 (0.12) [269] 2.97 (0.13) [273] 2.70 (0.12) [274]
Psoriasis-affected BSA, mean % (S.D.) 12.7 (18.8) 10.8 (14.7) 10.7 (15.6)
sPGA, mean (S.D.) [n] 2.6 (1.1) [281] 2.6 (1.0) [284] 2.5 (1.0) [283]
Swollen Joint Count (66 joints), mean (S.D.) [n] 12.9 (9.9) [284] 11.5 (9.6) [283] 11.2 (9.1) [282]
Tender Joint Count (68 joints), mean (S.D.) [n] 20.9 (15.0) [284] 18.8 (14.5) [283] 20.0 (15.3) [282]
Swollen Joint Count (28 joints), mean (S.D.) [n] 7.7 (5.4) [284] 6.8 (5.4) [283] 6.7 (5.0) [282]
Tender Joint Count (28 joints), mean (S.D.) [n] 10.9 (7.4) [284] 9.5 (7.0) [283] 9.9 (7.4) [282]
Tender Dactylitis Count, mean (S.E.) [n] 2.3 (0.2) [284] 2.2 (0.2) [283] 2.4 (0.3) [282]
Leeds Dactylitis Index Score >0 at baseline, n (%) 98 (34.5) 96 (33.8) 90 (31.8)
Mean (S.E.) [n] for patients with >0 at baseline 164.9 (26.9) [98] 147.6 (20.8) [96] 138.2 (23.9) [90]
Leeds Enthesitis Index Score, mean (S.E.) [n] 1.5 (0.1) [284] 1.6 (0.1) [283] 1.7 (0.1) [282]
SPARCC Enthesitis Score >0 at baseline, n (%) 191 (67.3) 189 (66.5) 196 (69.3)
Mean (S.E.) [n] for patients with >0 at baseline 5.7 (0.3) [191] 5.5 (0.3) [189] 5.9 (0.3) [196]
Physician Global Assessment (0–100), mean (S.D.) [n] 58.6 (19.4) [284] 58.3 (18.2) [284] 58.0 (17.8) [282]
Patient Global Assessment (0–100), mean (S.D.) [n] 60.7 (22.5) [283] 62.9 (22.1) [284] 61.0 (20.8) [282]
Patient Global Assessment of pain (0–100), mean (S.D.) [n] 56.1 (21.7) [283] 56.5 (22.3) [284] 55.7 (21.6) [282]
SF-36 PCS, mean (S.D.) [n] 35.6 (8.4) [282] 37.8 (8.4) [284] 37.4 (9.2) [282]
DAS28-CRP, mean (S.D.) [n]; scores range from 2 to 10 4.93 (1.11) [283] 4.80 (1.13) [281] 4.75 (1.12) [281]
CDAI, mean (S.D.) [n]; scores range from 0 to 76 30.51 (13.26) [283] 28.45 (12.89) [283] 28.55 (12.71) [281]
SDAI, mean (S.D.) [n]; scores range from 0 to 86 31.56 (13.52) [283] 29.52 (13.19) [281] 29.43 (12.90) [281]
DAPSA, mean (S.E.) [n]; scores range from 0 to 144 þ CRP 46.5 (1.4) [283] 43.4 (1.4) [281] 43.8 (1.4) [281]
PASDAS, mean (S.E.) [n]; scores range from 0 to 10 6.09 (0.07) [282] 6.05 (0.07) [279] 6.04 (0.07) [280]
a[n] is the number of patients analyzed for mean values (if the number is different from the full analysis set). BSA: body
surface area; CDAI: Clinical Disease Activity Index; DAPSA: Disease Activity Index for Psoriatic Arthritis; DAS28-CRP:
Disease Activity Score (28 joints) using CRP; DMARD: disease-modifying antirheumatic drug; mTSS: van der Heijde modi-
fied Total Sharp Score; PASDAS: Psoriatic Arthritis Disease Activity Score; PsA: psoriatic arthritis; Q1: first quartile; Q3:
third quartile; SDAI: Simplified Disease Activity Index; SF-36 PCS: Short Form 36 (health survey) Physical Component
Summary; SPARCC: Spondyloarthritis Research Consortium of Canada; sPGA: static Physician Global Assessment.
Laura C. Coates et al.
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with PASDAS; the difference between combination ther-
apy and MTX monotherapy ranged from 0.12–0.29
across the four joint-focused measures and was 0.59
with PASDAS. The difference in standardized responses
between etanercept monotherapy and MTX monother-
apy (Fig. 1B), ranged from 0.20–0.29 across the four
joint-focused measures and was 0.4 with PASDAS; the
difference between combination therapy and MTX
monotherapy ranged from 0.05–0.14 across the four
joint-focused measures and was 0.28 with PASDAS.
These data further indicate that of the five continuous
composite measures examined, PASDAS generated
results that most closely mirrored those obtained with
the dichotomous composite measures.
Degree of individual component contribution to the
continuous composite measures
Analyses examined the contribution of each component
change to the overall changes in continuous composite
scores from baseline at week 24. Across DAPSA,
DAS28-CRP, CDAI and SDAI, the main drivers were
TABLE 2 Composite endpoint responses at week 24
Composite endpoint
responsea
MTX
monotherapy
(n5 284)
Etanercept
monotherapy
(n5 284)
P-valueb for MTX
monotherapy vs
etanercept
monotherapy
Combination
therapy
(n5283)
P-valueb for MTX
monotherapy vs
combination
therapy
ACR 20, n/N (%) 144/284 (50.7) 173/284 (60.9) P50.029 184/283 (65.0) P50.005
ACR 50, n/N (%) 77/252 (30.6) 114/257 (44.4) P¼0.006 117/256 (45.7) P<0.001
ACR 70, n/N (%) 35/253 (13.8) 75/257 (29.2) P<0.001 71/256 (27.7) P<0.001
MDA, n/N (%) 65/284 (22.9) 102/284 (35.9) P50.005 101/283 (35.7) P50.005
VLDA, n/N (%) 12/252 (4.8) 39/257 (15.2) P<0.001 37/258 (14.3) P<0.001
DAS28-CRP, mean (S.E.)
change from baseline [n]a
1.55 (0.08) [251] 1.97 (0.08) [253] P<0.001 1.86 (0.08) [256] P¼0.01
CDAI, mean (S.E.) change
from baseline [n]
15.74 (0.85) [249]17.12 (0.78) [257] P¼0.26 16.43 (0.85) [256] P¼0.59
SDAI, mean (S.E.) change
from baseline [n]
15.96 (0.86) [248]17.75 (0.81) [253] P¼0.15 17.01 (0.87) [256] P¼0.41
DAPSA, mean (S.E.) change
from baseline [n]
22.59 (1.4) [251] 24.99 (1.3) [253] P¼0.24 24.92 (1.4) [256] P¼0.23
PASDAS, mean (S.E.) change
from baseline [n]
1.98 (0.10) [246] 2.64 (0.10) [250] P<0.001 2.63 (0.11) [255] P<0.001
a[n] is the number of patients examined for mean values if different from the primary analysis set. bP-values in bold had
statistical significance; all others are unadjusted and are italicized. CDAI: Clinical Disease Activity Index; DAPSA: Disease
Activity Index for Psoriatic Arthritis; DAS28-CRP: Disease Activity Score (28 joints) using CRP; MDA: Minimal Disease
Activity; PASDAS: Psoriatic Arthritis Disease Activity Score; SDAI: Simplified Disease Activity Index; VLDA: Very Low
Disease Activity.
FIG. 1 Effect size and standardized response of the composite measures by treatment group at week 24.
Effect Size ¼ (baseline mean  post baseline mean)/s.d. of baseline mean. Standardized Response ¼ (baseline mean
 post baseline mean)/ s.d. of change from baseline for that visit in the same treatment group. CDAI: Clinical Disease
Activity Index; DAPSA: Disease Activity Index for Psoriatic Arthritis; DAS28-CRP: Disease Activity Score (28 joints)
using CRP; ETN: etanercept; PASDAS: Psoriatic Arthritis Disease Activity Score; SDAI: Simplified Disease Activity
Index.
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changes in Tender and Swollen Joint Counts with much
less contribution made by changes in Physician and
Patient Global Assessments, Patient Global Assessment
of Joint Pain, and CRP (Table 3). In contrast, the main
drivers of results in PASDAS were changes in the
Physician and Patient Global Assessments of disease
activity (Table 4). Changes in the Leeds Enthesitis Index
and Tender Dactylitis Count contributed little to the
PASDAS results when analysing the full patient analysis
set. However, the contribution of changes in the Leeds
Enthesitis Index to the PASDAS score became more
prominent when a patient subset with Leeds Enthesitis
Index scores >0 at baseline was analysed (Table 4).
Similarly, the contribution of changes in Tender
Dactylitis Count to the PASDAS score change notably
increased in the patient subgroup with Tender Dactylitis
Count >0 at baseline (Table 4). Across the composite
measures examined, the contribution of CRP to the
overall changes in response to treatment was minor. To
more easily visualize the relative contribution of each
component to the composite score change at week 24
from baseline, pie charts were generated showing the
percentage contribution of each component’s median
value to the overall composite score in each treatment
group (Fig. 2).
Mean values generated for the contribution of each
component to the change in continuous composite
scores at week 24 from baseline showed a lack of con-
sistency between treatment groups for each component
(Tables 3 and 4). Large CIs associated with the mean
values suggest that data were skewed and/or that the
variation in patient disease characteristics was high. In
contrast, median values for the contribution of each
component to composite score changes from baseline
to week 24 were fairly similar between treatment groups
for each of the components.
Discussion
The analyses described here compared the responsive-
ness of the DAS28-CRP, CDAI, SDAI, DAPSA and
PASDAS continuous composite measures used in the
SEAM-PsA trial. Overall, the PASDAS results were the
most consistent with the ACR 20 and MDA results. In
addition to most closely mirroring the protocol-defined
primary and key secondary endpoints, PASDAS also
showed the largest treatment differences and largest
standardized response in this study. These findings indi-
cate that of the continuous composite measures exam-
ined, PASDAS may have the strongest ability to detect
treatment-associated changes in PsA disease activity.
Several other trials in which different PsA continuous
composite measures [including DAS28, DAPSA,
PASDAS, CPDAI and GRAppa Composite Score
(GRACE)] were compared have also concluded that
PASDAS performed the best of the measures examined
[3, 11, 14, 23]. In contrast to these previously published
analyses that examined data from placebo-controlled
studies, SEAM-PsA is one of the first active-comparator
studies in PsA that utilized composite measures to
examine disease activity. Though composite measures
may perform differently in active-comparator studies
compared with placebo-controlled RCTs, data from
SEAM-PsA were consistent with previous studies in indi-
cating that PASDAS was the most responsive of the
composite measures examined.
Our analysis of which individual components drive the
results for the five continuous composite measures
showed that DAPSA, DAS28-CRP, CDAI and SDAI were
mainly driven by joint counts, while PASDAS was mainly
driven by the global assessments. When examining the
contribution of each individual component change to the
overall changes in composite scores from baseline to
week 24, there were differences in the consistency of
results across treatment groups when comparing mean
and median values. The wide CIs associated with the
mean changes may be owing to inclusion, in this global
study, of patients that had different disease patterns
and/or variability in disease duration before receiving
treatment. The fact that different people completed the
assessments may also be a contributing factor. The me-
dian values for each individual component change
showed more consistency between treatment groups,
suggesting that the use of medians may better represent
group data. The median changes indicated that the type
of treatment received in each treatment group appeared
to have little effect on the relative contributions of
changes in individual components to the overall changes
in composite scores from baseline to week 24.
Though DAPSA and PASDAS were both developed
specifically for use in PsA [8, 9], the SEAM-PsA results
described here indicated that PASDAS was consistently
the measure most sensitive to change and that DAPSA
was not able to discriminate between the treatment
groups. DAPSA was designed to measure peripheral
arthritis and does not include a measure of enthesitis or
dactylitis. In contrast, PASDAS includes both specific
assessments of enthesitis and dactylitis severity as well
as global assessments, which are likely to reflect dis-
ease activity in multiple domains. That PASDAS may be
adaptive to the influence of various PsA manifestations
was reflected in how those patient subgroups with
enthesitis or dactylitis count >0 at baseline produced
results showing a higher input of the enthesitis or dacty-
litis component changes to the overall composite
PASDAS score change at week 24 (Table 4). Overall, the
data presented here suggest that composite measures
that include multiple domains, such as PASDAS, are
better at quantifying the PsA disease burden as they ap-
pear to show the greatest sensitivity to change and bet-
ter represent the breadth of disease manifestations.
Strengths of the analyses presented here include that
the data were from a large, active-comparator, double-
blind RCT in PsA with over 280 patients in each treat-
ment group, which allowed for comparisons between
the treatment groups. In addition, the trial collected data
from 10 composite measures used in PsA (five dichot-
omous measures and five continuous measures). Key
Laura C. Coates et al.
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limitations of the analyses include that SEAM-PsA was
neither designed nor powered for studying continuous
composite outcomes individually (thus, the P-values
generated for the composite measure analyses were de-
scriptive). In addition, these analyses may have some
limitations regarding their generalizability and may be
best applicable to the type of patients included in
SEAM-PsA with predominantly polyarticular disease,
MTX naı¨ve, and with early PsA disease. Though extrapo-
lating findings from an RCT to the real-world population
of patients with PsA can be challenging, results from
this trial can inform the planning of future trials (espe-
cially active-comparator trials) that use composite meas-
ures to evaluate PsA therapies administered to patients
with early 1disease.
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